AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson’s diseaseClear safety profile with no clinically relevant safety issues reportedTargets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessmentsUnderlines potential and importance of ...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3 registration ...

NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term exclusivity for the ...

BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (ICP-723), has received approval from the China National Medical Products Administration (NMPA) for the treatment of adult and adolescent patients (aged 12 years and older) with solid tumors harboring NTRK gene fusions. In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletr ...

Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara’s Board of Directors, effective Jan ...

股价表现与交易数据 - 公司股票在周三盘后交易中大幅上涨8.41%，达到27.77美元[1] - 公司股票周三收盘价为25.62美元，当日下跌6.84%[1] - 公司股票在过去六个月中大幅反弹388%，但年初至今仍下跌60.58%[5] - 公司当前市值为4577万美元，52周交易区间为7.25美元至72.50美元[5] 机构持股披露 - Janus Henderson Group plc提交了13G表格，披露其持有公司170,097股股票，占公司普通股的9.99%[2] - 在总持股中，Janus Henderson的子公司Janus Henderson Biotech Innovation Master Fund Ltd持有118,196股，占该类别的6.6%[3] - 披露的持股总数包含可在60天内行使的预融资权证和普通权证，但受限于9.99%的实益所有权上限[2] - 另有8,562份预融资权证、182,000份J系列普通权证和182,000份K系列普通权证因所有权上限规定未计入报告数据[4] - 提交文件显示，相关实体对其持股共享投票权和处置权，无单独权力[3] - 文件由公司北美合规主管兼首席合规官Kristin Mariani签署[4]

合作公告核心 - 生物技术社会企业Phare Bio与商业阶段生物制药公司Basilea Pharmaceutica宣布建立战略合作伙伴关系，旨在共同开发一种新型广谱抗生素，以解决由高优先级革兰氏阴性病原体引起的危及生命的感染患者的关键未满足需求 [1] 合作模式与分工 - 此次合作标志着抗生素研发领域的历史性首次：将患者和目标产品特征置于人工智能驱动发现的最前沿，同时确保有工业合作伙伴致力于推进可行的候选药物进入临床开发 [2] - 根据协议，Phare Bio将部署其生成式人工智能平台（该平台已用类药特性进行独特参数化）来设计符合预定义目标产品特征的分子；在识别出符合该特征的分子后，Basilea将承担后续开发责任，而Phare Bio将有资格获得基于成功的预定义付款 [3] - 该合作代表了一种抗生素创新的新模式，将药物发现的技术进步与工业专长及经济可持续性相结合 [3] 公司高层评论 - Phare Bio总裁兼首席执行官Akhila Kosaraju博士称此次合作是抗菌素耐药性领域的一个分水岭时刻，首次将其尖端的人工智能药物发现平台与致力于开发创新药物以满足新型抗生素需求的合作伙伴结合起来，并验证了其非营利性创新与私营部门合作的混合模式是解决当今最重大公共卫生危机之一的可行途径 [4] - Basilea首席执行官David Veitch表示，与Phare Bio的合作反映了公司在抗生素发现和开发方面的创新承诺，其人工智能平台可能为加速开发新型抗菌疗法带来变革性解决方案，支持公司提供满足紧迫医疗需求的差异化疗法的战略 [4] 公司背景信息 - Phare Bio是一家利用人工智能开发新型抗生素的生物技术社会企业，成立于2020年，旨在应对全球抗生素耐药性危机，它将尖端机器学习与世界一流科学相结合，以加速急需抗生素的发现，并得到The Audacious Project、Google.org、ARPA-H等机构的支持 [5] - Basilea是一家商业阶段的生物制药公司，成立于2000年，总部位于瑞士，致力于发现、开发和商业化创新药物以满足严重细菌和真菌感染患者的需求，已成功推出两个医院品牌：用于治疗侵袭性真菌感染的Cresemba和用于治疗细菌感染的Zevtera，此外其产品管线中还拥有临床前和临床抗感染资产，公司在瑞士证券交易所上市 [6]

Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a partnership with Phare Bio Inc., Boston (USA), a biotech social venture that uses Artificial Intelligence (AI) to accelerate antibiotic discovery and development. Under the partnership, Phare Bio will deploy its Generative AI platform to design molecules with antibacte ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) initially entered into on January 30, 2024. The at-the-market offering program en ...

分析师持仓披露 - 分析师通过股票持有、期权或其他衍生品对IMMX拥有实质性的多头头寸 [1] - 文章内容为分析师个人观点，且未因撰写此文获得任何报酬 [1] - 分析师与文中提及的任何公司均无业务关系 [1] 平台免责声明 - 过往表现不保证未来结果，文章内容不构成任何投资建议 [2] - 所表达的观点可能不代表Seeking Alpha的整体意见 [2] - Seeking Alpha并非持牌证券交易商、经纪商或美国投资顾问/投资银行 [2] - 平台分析师为第三方作者，包括专业和散户投资者，其资质可能未经任何机构或监管机构认证或许可 [2]